Adverse events · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · people with intermediate‐stage hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Secondary malignant neoplasms · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone may leads to lower secondary malignant neoplasms compared with same chemotherapy plus radiotherapy (low certainty).
1 finding from 1 review
Death · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in death compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Progression/relapse · Patients with untreated Hodgkin lymphoma (early and advanced stages)
Chemotherapy alone showed no clear difference in progression/relapse compared with same chemotherapy plus radiotherapy (moderate certainty).
1 finding from 1 review
Overall survival · people with advanced gastric cancer
Chemotherapy probably leads to lower overall survival compared with best supportive care (moderate certainty).
1 finding from 1 review
Time to progression · people with advanced gastric cancer
Chemotherapy probably leads to lower time to progression compared with best supportive care (moderate certainty).
1 finding from 1 review
Premature ovarian failure · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Pregnancy · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes pregnancy compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Ovulation · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Adverse events · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Menstruation recovery or maintenance: · premenopausal women with malignant conditions, receiving GnRH agonist before or in parallel to chemotherapy
It is very uncertain whether gnRH agonist‐antagonist cotreatment plus chemotherapy changes menstruation recovery or maintenance: compared with chemotherapy alone (very low certainty).
2 findings from 1 review
Overall survival · patients with asymptomatic, incurable, metastatic colorectal cancer
Delayed chemotherapy showed no clear difference in overall survival compared with immediate chemotherapy (low certainty).
1 finding from 1 review
Nausea and vomiting · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – nausea and vomiting compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – stomatitis · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – stomatitis compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Toxicity – diarrhoea · patients with asymptomatic, incurable, metastatic colorectal cancer
It is very uncertain whether delayed chemotherapy changes toxicity – diarrhoea compared with immediate chemotherapy (very low certainty).
1 finding from 1 review
Quality of life · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review
Progression‐free survival · patients with asymptomatic, incurable, metastatic colorectal cancer
1 finding from 1 review